A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Titration, Multi-center Study to Evaluate the Safety and Efficacy of Subcutaneous MANP When Administered Once Daily for 42 Days in Participants with Difficult to Control Hypertension/Resistant Hypertension.
Condition: Hypertension
Drugs: MANP
Trial ID: BOLD-HTN
Age: 18-80 years old (inclusive)
Phase: 2
